# Credo: more stock pay than free cash in the latest quarter CRDO, NASDAQ. Published October 3, 2026. Price as of the October 2, 2026 regular session close. ## Verdict: REDUCE at $218.64 Credo's revenue grew 115% to $479.0 million last quarter, with a non-GAAP operating margin of 48.2%. At $218.64 the shares are 46% above my Base value of $150 and 9% below my Bull value of $240. The buy zone is $75 to $90. - Bear value: $92 - Base value: $150 - Bull value: $240 - Downside to base value: -31.5% - Maximum buy price: $90 - Required margin of safety: 40% - Enterprise value / fiscal 2027 consensus free cash flow: 51.4x - Free cash flow implied by the price at 34.5x: about $1.25 billion (consensus $827 million) - Business quality: 80/100 - Valuation score: 27/100 - Confidence: 16/25, grade C In the quarter ended August 1, 2026, Credo's revenue grew 115%. In the same quarter it spent $88.0 million in stock-based compensation and produced $82.9 million of free cash flow. The first number is the story the stock has been selling. The second is the one the per share math has to live with. At the October 2, 2026 close of $218.64 the shares trade 46.1% above my triangulated Base value of $149.66, a downside of 31.5%. The Bear value of $92 is 57.7% below the price. The Bull value of $240 is 9.8% above it, so the price sits between my Base and my Bull. The framework's required margin of safety (MOS) for this profile is 40%, which puts the maximum buy price at $90. The shares would have to fall about 59% to get there. Route: SF-15 Semiconductors and ecosystem, subtype fabless. Economic classification: Quality Growth (7/12). Primary method: justified multiple of fiscal 2027 free cash flow per share. Secondary method: ten-year free cash flow model. Credo's fiscal year ends close to April 30, so fiscal 2027 runs from May 2026 to April 2027. Values are present fair value estimates, not 12 month price targets. ## What Credo is Credo designs the chips and cables that move data between servers, switches and memory inside AI data centers. Its main product is the active electrical cable (AEC): a copper cable with a Credo chip in each connector that cleans and boosts the signal. It also sells retimers, DSPs (digital signal processors) and licenses its SerDes technology (the circuitry that turns data into a high speed signal). Credo does not make its own chips; it hires foundries and assemblers. In the latest quarter AECs drove more than 90% of the revenue increase, and management says optical revenue should pass $600 million in fiscal 2027. Optical is the reason for the largest decision of the year. On May 28, 2026 Credo closed the purchase of DustPhotonics, a silicon photonics chip designer. The 10-Q puts the total consideration at $1.25 billion: $769.6 million in cash, $169.1 million in shares (about 0.76 million), and $310.0 million of contingent consideration payable in up to about 3.21 million more shares if financial milestones are met. Goodwill and intangibles now total $1.37 billion, 45% of total assets and 50% of shareholders' equity. Concentration is the other side. By end customer, the three largest were 28%, 33% and 13% of last quarter's revenue and a fourth was 10%, as reported in the 10-Q. By contracting party, Customer A was 43% of revenue and 57% of receivables. Contracted but unsatisfied performance obligations were $4.2 million at quarter end, against $479.0 million of quarterly revenue, so orders carry almost no commitment. ## The latest quarter | Q1 fiscal 2027 (quarter ended August 1, 2026) | Result | | --- | --- | | Revenue | $479.0 million, up 114.7% year over year and 9.6% from the fourth quarter | | Gross margin | GAAP 64.5% (fourth quarter 68.2%), non-GAAP 68%. The GAAP gap is mostly $11.0 million of acquired intangible amortization. | | Operating income | GAAP $120.7 million (25.2% margin, fourth quarter 35.7%), non-GAAP $230.6 million (48.2%) | | Net income | GAAP $129.4 million ($0.67 a diluted share), non-GAAP $236.3 million (about $1.20 a share). The gap is $106.9 million. | | Cash flow | Operating cash flow $90.2 million, capital spending $7.3 million, free cash flow $82.9 million. Working capital absorbed $151.3 million. | | Stock-based compensation | $88.0 million, up 148% from $35.5 million a year earlier and 18.4% of revenue | | Liquidity | $466.9 million of cash and $297.4 million of short-term investments, no financial debt | | Q2 outlook | Revenue $525 million to $535 million, non-GAAP gross margin 67% to 69%, GAAP gross margin 62.9% to 64.9%, non-GAAP operating expenses $100 million to $105 million | The press release calls the non-GAAP net margin 49.3%. The GAAP net margin is 27.0%. Both are correct, and the difference is mostly the $88.0 million of stock compensation, which the first one leaves out and the second one pays. ## Why free cash flow needs the stock compensation line next to it Fiscal 2026 free cash flow was **$407.0 million**: operating cash flow of $464.3 million minus capital spending of $57.3 million. After $182.6 million of stock-based compensation (SBC), a real cost paid in shares, the hard figure is **$224.4 million, or 55.1% of the headline**. In the latest quarter the hard figure is negative, at -$5.1 million. My valuation uses the headline figure, as consensus does, and charges SBC through the multiple and the discount rate. The adversarial review shows what happens if the full cost is deducted instead. Fiscal 2027 consensus free cash flow is about **$827 million** (third-party datasets, which I could not reproduce). The first quarter delivered $82.9 million, so the remaining three quarters have to average about $248 million each. The best quarter on record is $177.5 million, in the fourth quarter of fiscal 2026. That is possible, since net income will be rising and the first quarter was held back by a $61.5 million inventory build and $25.3 million of refundable capacity deposits, but Credo has also agreed to pay a further $102.4 million of such deposits within the year. ## Balance sheet and shares Credo has no financial debt. Cash and short-term investments were **$764.3 million** on August 1, down from $1,443.3 million on May 2 after the DustPhotonics payment. I use $764.3 million as net cash and leave out $26.2 million of operating lease liabilities, because rent is already paid out of the cash flow. The first draft deducted them and used $738 million, a difference of $0.13 a share. Shares are where the problem sits. Shares outstanding went from 171.2 million at the end of fiscal 2025 to 185.4 million a year later (+8.3%) and 187.8 million on August 1. In fiscal 2026 the company raised $736.3 million through an at-the-market stock offering, almost twice the free cash flow of the year. First quarter weighted diluted shares were 194.4 million against 184.6 million a year earlier (+5.3%), and management guides to about 200 million for the second quarter. Unvested employee awards are 8.3 million restricted units, 3.1 million performance units and 1.7 million options, and the new fiscal year's grants were made at $226.57 and $155.39 a share. I use 198 million forward diluted shares for all per share values, and test 201.2 million, which adds the maximum contingent DustPhotonics shares. ## Primary valuation: a justified multiple of free cash flow per share Fiscal 2027 consensus free cash flow of $826.9 million divided by 198 million shares is **$4.18 a share**. A multiple of 33x to 36x, which is meant to reflect growth and quality net of concentration, dilution and cycle risk, gives $137.82 to $150.35. The midpoint of 34.5x gives **$144.08**. The first draft showed the central value as $145; I use the unrounded figure. The multiple is my assumption, not the output of a build, so the grid below tests it. ### Sensitivity: value per share | Fiscal 2027 free cash flow \ multiple | 31.5x | 34.5x | 37.5x | | --- | --- | --- | --- | | $660 million (20% below consensus) | $105.0 | $115.0 | $125.0 | | $827 million (consensus) | $131.6 | $144.1 | $156.6 | | $950 million (high case) | $151.1 | $165.5 | $179.9 | No cell reaches $218.64. The highest, 37.5x on a free cash flow of $950 million, gives $179.9. ## Secondary valuation: ten-year free cash flow model The secondary method does not use the multiple. It starts from fiscal 2026 free cash flow of $407.0 million, grows it along an explicit path, discounts it, and adds net cash of $764.3 million, all divided by 198 million shares. The first draft gave the Base growth path but no inputs for the Bear and Bull cases, so the paths below for those two are mine and are estimates. | | Bear | Base | Bull | | --- | --- | --- | --- | | Free cash flow, fiscal 2027 | $700 million | $826 million | $948 million | | Growth, years 2 to 10 | 32% fading to 4% | 35% fading to 5% | 40% fading to 5% | | Free cash flow, year 10 | $2.18 billion | $3.19 billion | $4.25 billion | | Discount rate / terminal growth | 11% / 2.5% | 10% / 3.0% | 9% / 3.0% | | Terminal value share of total | 53% | 61% | 66% | | Value per share | $92.46 | $154.23 | $240.08 | Base growth runs 103%, then 35%, 28%, 22%, 18%, 14%, 11%, 9%, 7% and 5%. The **secondary Base is $154.23**. The Bear case is not a collapse: it still has free cash flow growing 5.4 times by year 10. For a harsher test, the Base path with fiscal 2027 free cash flow 40% lower gives $94. ### Sensitivity of the Base model: value per share | Discount rate \ terminal growth | 2.0% | 2.5% | 3.0% | | --- | --- | --- | --- | | 9% | $165 | $173 | $183 | | 10% | $142 | $148 | $154 | | 11% | $124 | $128 | $133 | ## Market multiples and growth diagnostics On trailing figures the shares trade at 77 times GAAP earnings, about 94 times trailing free cash flow (trailing twelve months of $438.6 million, which I calculated) and about 26 times trailing revenue. A synchronized multiple history is not available from free sources, so I do not use one. The growth valuation cross-check (SM-19) is a diagnostic only. Fiscal 2027 adjusted earnings per share are expected at about $6.31 (third-party estimate) against $3.46 in fiscal 2026, an increase of 82.4%. At $218.64 that is a forward P/E of 34.6x and a forward PEG of about 0.42. The first draft said 30x and 0.37. Either figure looks cheap and proves nothing, because the adjusted earnings leave out SBC and intangible amortization, which are the difference between $1.20 and $0.67 a share last quarter. Growth durability: structural and normalizing. Cyclical distortion: medium, because demand depends on a few hyperscaler capital spending programs. Flag: accounting basis mismatch. SM-19 does not set fair value. The free cash flow growth quality check (SM-20) starts from $407.0 million in fiscal 2026 and ends at the consensus $826.9 million in fiscal 2027: an increase of $419.9 million, or 103%, in one year. Per share, using fiscal 2026 non-GAAP diluted shares of 191.3 million and 198 million for fiscal 2027, that is $2.13 rising to $4.18, or 96%. Free cash flow margin goes from 30.5% to about 33% on consensus revenue of $2.5 billion. Yields at today's price are 1.1% on trailing free cash flow and 2.0% on fiscal 2027. Distortion flags: low base medium, acquisition high, working capital high, capital spending timing low, dilution high. Estimate reliability: medium. Classification: structural with execution risk. I do not publish a numeric SM-20 score, since the first draft's 76/100 came with no breakdown. SM-20 does not set fair value, MOS or the verdict. ## Valuation triangulation | Method | Base value | Weight | | --- | --- | --- | | Primary: 34.5x fiscal 2027 free cash flow per share | $144.08 | 45% | | Secondary: ten-year free cash flow model | $154.23 | 55% | | Triangulated Base | $149.66 | 100% | The two methods differ by 6.8%, under the 20% warning threshold. That agreement is weaker evidence than it looks, because both lean on the same fiscal 2027 consensus. The first draft stated 45% and 55% weights, which give about $150, and then raised the Base to $155 by judgment to reflect strong guidance. I do not round the Base above its methods, so the Base is $149.66. The Bear ($92.46) and Bull ($240.08) are the model values above; the multiple method has no scenario inputs, so it applies to the Base only. ## What is the market already pricing in? At $218.64 and 198 million diluted shares, market value is about $43.3 billion and enterprise value about **$42.5 billion**. That is 51.4x fiscal 2027 consensus free cash flow, 17.0x consensus revenue of $2.5 billion and 31.9x fiscal 2026 revenue of $1.34 billion. At my 34.5x multiple the price needs fiscal 2027 free cash flow of about **$1.25 billion**, 52% above consensus. In the model, the price equals the Base path scaled up by about 1.43 times (fiscal 2027 free cash flow near $1.18 billion), or the Base path at a discount rate of about 8.1%. A buyer today needs several things to be true: growth stays above 25% for years, the optical business is integrated and scales, the largest customers keep buying without long term commitments, margins hold near 68% non-GAAP, stock compensation stops growing faster than free cash flow, and the share count stabilizes. The price is not asking for a good outcome. It is asking for something close to the Bull. ## Bear, base and bull scenarios | | Bear | Base | Bull | | --- | --- | --- | --- | | Main assumptions | Slower optical ramp, order volatility at the largest customers, persistent dilution, higher discount rate | Fiscal 2027 consensus broadly achieved, gradual growth fade, strong margins | Sustained share gains, optical integrated well, customer concentration falls, lower discount rate | | Free cash flow, fiscal 2027 | $700 million | $827 million | $948 million | | Value per share | $92 | $150 | $240 | | Versus $218.64 | -57.7% | -31.5% | +9.8% | I assign no probabilities to the scenarios. Only the Bull sits above the price, and by 9.8%. The price is the Bull, less a little. ## How the buy price is set A Confidence C score carries a base MOS of 35%. I add 5 points for customer concentration and model risk, and nothing for the balance sheet, because cash is under 2% of the company's value. The required MOS is **40%**. Applied to the $149.66 Base, the **maximum buy price is $90** ($89.80), and a stronger 50% margin marks a strong-buy reference near $75. Charging SBC explicitly, as the stress test in the review does, would justify 45% and a maximum buy price near $82. The first draft also listed a practical buy zone of $90 to $105. A price above the maximum buy price does not carry the required margin of safety, so I drop it. The buy zone is $75 to $90, and the shares would need to fall about 59% from $218.64 to reach $90. ## Dividend and capital return Credo pays no dividend and does not buy back shares, so the income check does not apply. Its capital activity has gone the other way: it sold $736.3 million of stock in fiscal 2026. ## Reasons to own CRDO - **AI clusters need more bandwidth per rack.** Credo's cables and chips address the short links where copper and optical choices are being made now. - **Proprietary SerDes and DSP technology.** Customers qualify these designs for years, which creates switching friction. - **Exceptional operating leverage.** Revenue is up 115%, non-GAAP gross margin is 68% and non-GAAP operating margin is 48.2%. - **Optical option.** DustPhotonics adds silicon photonics and design wins with hyperscale customers. - **No financial debt.** $764.3 million of cash funds research and integration. ## What could go wrong? - **Thesis breaker: a major customer or design win lost while the valuation stays at a premium.** Four end customers are 84% of revenue, and one contracting party is 57% of receivables. - **Valuation.** At 51 times fiscal 2027 free cash flow, a smaller multiple can outweigh years of good growth. The 52 week range is $86.49 to $308.67, and the shares are 29% below the high. - **SBC and dilution.** Stock compensation was larger than free cash flow in the latest quarter, the share count is up 8.6% in a year, and up to 3.21 million contingent shares are still to come. - **Working capital and supply.** Inventory rose 24.8% in one quarter against revenue growth of 9.6%. Credo has $222.2 million of purchase commitments and depends on third-party foundries and assemblers. - **Acquisition execution.** $1.37 billion of goodwill and intangibles now sit on the balance sheet, with $58.2 million a year of amortization to come from fiscal 2028. - **Hyperscaler spending cycle.** Orders carry no long term minimums and only $4.2 million of performance obligations were contracted. ## Management execution Management has beaten its revenue guidance, scaled revenue more than threefold in fiscal 2026 and closed a large acquisition in the same year. The offsets are a rising share count that has not matched the growth in the business, a 10-K that describes special performance awards with six revenue and stock price hurdles (the first at $244.70), and an acquisition that has to be integrated while the largest customers decide where to buy optics. **Assessment: 15/20, good. The next test is whether free cash flow per share grows faster than SBC.** ## Stock Analyza scorecard | Economic classification | Score | | --- | --- | | Normalized return on invested capital | 1/2 | | Revenue growth, multi-year | 2/2 | | Free cash flow per share growth | 1/2 | | Balance sheet | 1/1 | | Unit economics | 1/1 | | Recurring and repeat economics | 0/2 | | Reinvestment runway | 1/2 | | Total: Quality Growth | 7/12 | The first draft scored 10/12, which mechanically means Compounder. Its own text then called Credo a Compounder candidate, which is not a class in the framework. Free cash flow per share growth is 1/2 because operating cash flow was negative $65.1 million in fiscal 2025, return on capital is 1/2 because the profitable record is short and now carries $1.25 billion of acquisition capital, and repeat economics are 0/2 because contracted obligations are $4.2 million. Business quality is **80/100**: moat and pricing power 17/20, return versus cost of capital 17/20, balance sheet 14/15, earnings and cash quality 9/15, growth and runway 14/15, management and capital allocation 7/10, dilution and governance 2/5. The valuation score is **27/100**: discount to Base 0/40, protection against the Bear case 0/20, agreement between methods 14/15, historical valuation 4/10, reverse valuation 5/10, data and model quality 4/5. ## Confidence score | Confidence | Score | | --- | --- | | Data quality / source provenance | 4/5 | | Predictability | 3/5 | | Valuation robustness | 3/5 | | Accounting transparency | 3/5 | | Scenario dispersion | 3/5 | | Total | 16/25, grade C | Reporting is timely and the balance sheet is clean. The grade is held down by concentration, a short profitable history, a large gap between GAAP and non-GAAP results, and the dependence of every method on fiscal 2027 consensus. ## What I would watch from here ### Green - Revenue growth above 40% - Non-GAAP gross margin at or above 66% - Free cash flow per share growth above 20% - Three largest end customers below 65% of revenue - Diluted share growth below 2% - SBC below 20% of free cash flow - Inventory growing no faster than revenue - Q2 revenue at or above the $525 million to $535 million guidance - Optical wins and ramp on schedule - Net cash above $500 million ### Yellow - Revenue growth 20% to 40% - Non-GAAP gross margin 62% to 66% - Free cash flow per share growth 0% to 20% - Three largest end customers 65% to 80% - Diluted share growth 2% to 5% - SBC 20% to 35% of free cash flow - Inventory growth up to twice revenue growth - A modest miss of Q2 guidance - Optical delays - Net cash $250 million to $500 million ### Red - Revenue growth below 20% - Non-GAAP gross margin below 62% - Falling free cash flow per share - Three largest end customers above 80% with weakening demand - Diluted share growth above 5% - SBC persistently above 35% of free cash flow - Inventory growth more than twice revenue growth - A major cut to guidance - Optical failure or write-down - Net cash below the funding needs of the business Today three readings are red: SBC (45% of free cash flow in fiscal 2026 and 106% in the latest quarter), diluted share growth (+5.3% weighted diluted and +8.6% outstanding) and inventory (+24.8% in one quarter against revenue +9.6%). The three largest end customers at 74% are yellow. Revenue growth (114.7%), non-GAAP gross margin (68%), free cash flow per share growth (about +53% on the first quarter) and net cash ($764.3 million) are green. The next review point is the second quarter report, expected around the end of November 2026 (an estimate). ## The three most important thesis breakers 1. The loss of a major hyperscaler or design win, or a shift of the largest customers to other suppliers. 2. A structural fall in gross margin, from competition or from the optical mix. 3. Dilution and SBC that keep growing faster than free cash flow per share. ## Adversarial review I recomputed the primary value, the ten-year model, the sensitivity grid, the triangulation, the MOS, the multiples and the share counts, and checked the reported inputs against the 10-K, the 10-Q, the first quarter release and the closing price. The reported figures reconcile. The corrections came in the Base, the scores, the SBC treatment and several statements. | Item | First draft | Corrected | | --- | --- | --- | | Base value | $155, raised by judgment above the weighted result of about $150 | $149.66 from the two methods. The downside moves from -29.1% to -31.5%, which crosses the framework's -30% line for Highly Overvalued, so the label changes from Hold / Reduce to Reduce. | | Bear and Bull | $95 and $241 with no growth path or inputs | Explicit paths: $92.46 and $240.08 | | Forward P/E and PEG | About 30x and 0.37 | 34.6x on $6.31 of expected earnings and 0.42 | | Buy zone | Maximum buy $93 but a practical zone of $90 to $105 | Maximum buy $90, zone $75 to $90 | | Valuation score | 34/100 with no breakdown | 27/100 from six components | | Economic classification | 10/12 (Compounder range), labeled Quality Growth / Compounder candidate | 7/12 Quality Growth, with reasons for each reduction | | Business quality and Confidence | 83/100 and 17/25 | 80/100 and 16/25: cash quality 11 to 9, dilution 3 to 2, accounting transparency 4 to 3 | | SBC and the dashboard | SBC at 45% of free cash flow listed without a red status; share growth listed as "rising" | Latest quarter SBC $88.0 million against free cash flow $82.9 million; SBC, share growth and inventory are all red today | | Contingent consideration | Not mentioned | $310.0 million fair value, up to 3.21 million shares, tested at 201.2 million shares | | Stock sold in fiscal 2026 | Not mentioned | $736.3 million through the at-the-market offering | | Net cash | $738 million, after deducting operating leases | $764.3 million, consistent with cash flow already carrying rent | | Customer concentration | 84% for three end customers in fiscal 2026 | Latest quarter from the 10-Q: 28%, 33%, 13% and a fourth at 10%. I did not reopen the fiscal 2026 figures. | | DCF sensitivity grid | Cells off by $2 to $3 (for example $127 at 11% and 2.0%) | Recomputed cell by cell | | SM-20 score | 76/100 with no components | Not published | The strongest counter-thesis, for the bulls: AI interconnect demand and the optical expansion could keep growth above 30% for much longer, which would make $150 too low. The response is that the Bull model, built on exactly that, gives $240, and the price of $218.64 already captures most of it. | Robustness check | Value per share | | --- | --- | | Base ten-year model | $154 | | Base model, whole path 20% lower | $124 | | Base model, whole path 40% lower | $94 | | Base model with 201.2 million shares (contingent shares issued) | $152 | | Base model with 200 million shares (management's Q2 guidance) | $153 | | Primary, fiscal 2027 free cash flow of $660 million at 34.5x | $115 | | Base model after estimated SBC ($400 million in fiscal 2027, growing 12% a year) | $103 | | Base model after estimated SBC growing 8% a year | $114 | | Primary after estimated SBC of $400 million in fiscal 2027 | $74 | | Triangulated Base after SBC (maximum buy price about $54) | $90 to $96 | | Base ten-year model at a 9% discount rate and 3.0% terminal growth | $183 | | Required margin of safety of 45% instead of 40% | Maximum buy price $82 | Audit flags: consensus fiscal 2027 revenue, earnings per share and free cash flow come from third-party datasets that I could not reproduce from free sources. The multiple of 34.5x and the Bear and Bull paths are my assumptions, not company guidance. The SBC path is my estimate: the first quarter's $88.0 million already reflects new grants, and the full-year figure could be higher or lower. The stress test overlaps partly with dilution, since the share count is already rising. The fiscal 2026 customer concentration percentages and the non-GAAP diluted share count of 197.5 million come from the first draft and I did not reopen them. No synchronized peer table is available. The publication gate status is PASS WITH WARNING because long-duration growth and consensus free cash flow remain uncertain. ## Final verdict: reduce at $218.64 Credo is a high-quality connectivity business growing at a rate few companies of its size have matched, and it ended the quarter with $764 million of cash and no debt. The shares, though, now trade 46% above my Base value and within 9% of my Bull, while the quarter's stock compensation was larger than its free cash flow. The growth is real. So is the bill. **Verdict: REDUCE at $218.64. Triangulated Base value $149.66, downside 31.5%, Confidence C (16/25). Required margin of safety 40%, maximum buy price $90.** The case changes if free cash flow per share starts growing faster than stock compensation and the share count, or if the price falls toward the buy zone with the business still executing. ## More analyses on Patreon This analysis is free. Premium members get every in-depth analysis, the full archive and a vote on which stocks get analyzed next: https://www.patreon.com/stockanalyza ## Sources Primary sources include Credo's [Form 10-Q for the quarter ended August 1, 2026](https://www.sec.gov/Archives/edgar/data/1807794/000162828026060111/crdo-20260801.htm), the [first quarter fiscal 2027 earnings release](https://www.sec.gov/Archives/edgar/data/1807794/000162828026059795/credoq12027ex-991.htm), the [Form 10-K for the fiscal year ended May 2, 2026](https://www.sec.gov/Archives/edgar/data/0001807794/000162828026043303/crdo-20260502.htm), the fourth quarter fiscal 2026 release and the earnings calls for both quarters. The October 2, 2026 close comes from [Yahoo Finance](https://finance.yahoo.com/quote/CRDO/). Consensus estimates and trailing multiples come from public aggregators cited in the framework analysis and are labeled as estimates. The reference market price is the October 2, 2026 regular session close of $218.64. A mobile trading app showed $217.96 after the close, within 0.3%. Balance sheet and cash flow figures are as of August 1, 2026, and the share count on the cover of the 10-Q is 187,951,918 as of August 25, 2026. The forward diluted share count, the ten-year paths, the 34.5x multiple and the SBC stress test are analytical estimates, not company guidance. **Disclaimer.** This analysis is provided solely for research and educational purposes. It is not personalized investment, financial, legal or tax advice. Credo is exposed to customer concentration, the cycle in AI data center spending, the integration of a large acquisition and ongoing dilution, and its shares are highly volatile. Investors can lose part or all of their invested capital. Framework: SF-15 Semiconductors, fabless. Economic class: Quality Growth. Engine: growth-adjusted multiple of free cash flow per share with a ten-year free cash flow cross-check. Confidence: C/16. Data status and adversarial gate: PASS\_WITH\_WARNING. Version: Master v3.3.